Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
GKOS Glaukos
47.820
-0.840-1.73%
Post Mkt Price
47.8200.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-4.61% 71.27M -6.93% 72.69M -0.42% 67.68M 30.70% 294.01M
Operating revenue
-4.61% 71.27M -6.93% 72.69M -0.42% 67.68M 30.70% 294.01M
Cost of revenue
9.70% 16.86M 0.42% 17.83M 2.59% 17.06M -27.36% 66.63M
Gross profit
-8.31% 54.41M -9.09% 54.85M -1.40% 50.62M 70.66% 227.38M
Operating expense
-2.93% 76.02M 22.88% 91.61M 12.17% 70.83M 13.03% 290.26M
Selling and administrative expenses
6.02% 47.15M 10.15% 49.9M 4.84% 43.95M 4.58% 179.26M
Research and development costs
-14.70% 28.87M 42.58% 41.71M 26.66% 26.88M 29.99% 111M
Operating profit
-13.89% -21.61M -158.47% -36.76M -71.18% -20.21M 49.11% -62.87M
Net non-operating interest income expense
12.33% -2.74M -2.23% -3.03M -9.94% -3.13M -2.97% -12.08M
Non-operating interest income
155.67% 744K 12.28% 384K -25.07% 287K -45.86% 1.29M
Non-operating interest expense
1.99% 3.48M 3.27% 3.41M 5.79% 3.42M -5.26% 13.37M
Other net income (expense)
-110.45% -2.98M -6,548.86% -5.85M 1,986.94% 29.04M 763.50% 25.69M
Special income (charges)
-- 0 -- 0 -- 30M -- 30M
-Less:Other special charges
-- -- -- -- -- -30M -- -30M
Other non- operating income (expenses)
-102.79% -2.98M -6,548.86% -5.85M 37.62% -960K -244.91% -4.31M
Income before tax
-524.89% -27.33M -164.22% -45.64M 135.23% 5.7M 62.77% -49.27M
Income tax
22.28% 247K -150.48% -105K 16.85% 326K 102.72% 326K
Net income
-542.63% -27.58M -160.47% -45.54M 132.65% 5.38M 58.79% -49.59M
Net income continuous Operations
-542.63% -27.58M -160.47% -45.54M 132.65% 5.38M 58.79% -49.59M
Minority interest income
Net income attributable to the parent company
-542.63% -27.58M -160.47% -45.54M 132.65% 5.38M 58.79% -49.59M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-542.63% -27.58M -160.47% -45.54M 132.65% 5.38M 58.79% -49.59M
Basic earnings per share
-546.15% -0.58 -152.63% -0.96 130.56% 0.11 60.37% -1.07
Diluted earnings per share
-546.15% -0.58 -152.63% -0.96 130.56% 0.11 60.37% -1.07
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion with Explanation

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
CEO: Mr. Thomas W. Burns
Market: NYSE
Listing Date: 06/25/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist